Spike Protein News and Research

RSS

Study reassures the safety, immunogenicity of COVID-19 vaccines for patients with rheumatic diseases

New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows that the COVID-19 vaccine was not associated with severe disease flares in patients with rheumatic diseases.

1 Nov 2021

Evidence antibodies targeting HCoV-OC43 are robustly boosted in response to SARS-CoV-2 but not vaccination

The magnitude of cross-reactive antibodies correlated well with responses to the SARS-CoV-2 spike protein and the S2 subdomain.

1 Nov 2021

SARS-CoV-2 antibodies persisting for nearly a year, including to delta: NZ study

A cohort study found that antibodies to the SARS-CoV-2 spike protein and neutralizing antibodies remain relatively stable 8-11 months post-infection.

1 Nov 2021

COVID-19 antibody levels stay more durable in vaccinated people with prior SARS-CoV-2 infection

In what is believed to be one of the largest studies of its kind, Johns Hopkins Medicine researchers have shown that antibody levels against SARS-CoV-2 (the COVID-19 virus) stay more durable — that is, remain higher over an extended period of time — in people who were infected by the virus and then received protection from two doses of messenger RNA (mRNA) vaccine compared with those who only got immunized.

1 Nov 2021

Curcumin, a bioactive component of turmeric, effectively neutralizes SARS-CoV-2 in vitro

The researchers investigated the neutralizing activity of turmeric root extract, curcumin-containing capsules, and pure curcumin against SARS-CoV-2.

1 Nov 2021

Identification of novel nanobodies to specifically target SARS-CoV-2 replication protein

Researchers have recently identified two nanobodies that show specific binding against a SARS-CoV-2 replication protein.

1 Nov 2021

Emerging SARS-CoV-2 variant A.30 efficiently evades vaccine-induced immunity

A recent study published in the journal Cellular & Molecular Immunology shows that a new A.30 variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can evade vaccine-induced antibodies and might spread outside the lungs extraordinarily well, with important implications for our public health response.

1 Nov 2021

The impact of SARS-CoV-2 variants on the COVID-19 epidemic in South Africa

A new study explores the role of new SARS-CoV-2 variants in sustaining the pandemic in South Africa.

31 Oct 2021

Study uncovers unknown effects of COVID-19 virus on the immune system

COVID-19 reduces the numbers and functional competence of certain types of immune cells in the blood, say LMU researchers. This could affect responses to secondary infections.

28 Oct 2021

How long does natural or vaccine-induced immunity to COVID last?

Researchers present a comprehensive assessment on SARS-CoV-2 induced immunity.

28 Oct 2021

Structure of human-infecting canine coronavirus HuPn-2018 spike glycoprotein

As CCoV-HuPn-2018 has been recently isolated in a child's respiratory swab, researchers from the University Of Washington have been examining the structure of the virus.

28 Oct 2021

Study finds one mRNA vaccine dose after SARS-CoV-2 infection produces highest neutralizing antibody titers

Researchers investigated the neutralizing antibody response that different mRNA vaccines induce in both previously convalescent and SARS-CoV-2 naïve individuals.

28 Oct 2021

Panel of broadly neutralizing SARS-CoV-2 nanobodies for immune assay application

In this study, a team of researchers from Japanese institutions provide a panel of broadly neutralizing nanobodies that detect four VOCs.

28 Oct 2021

Japanese study on SARS-CoV-2 breakthrough infections

Researchers evaluated SARS-CoV-2 incidence in Japan regarding the timing of the vaccination program and surge in COVID-19 cases among the staff of a large referral hospital in Tokyo. This study is posted to the medRxiv* preprint server.

28 Oct 2021

The difference in the dynamics of SARS-COV-2 variants

A new study provides a detailed description of the varying interactions between SARS-CoV-2 and the host cell ACE-2 receptor.

27 Oct 2021

A study on the SARS-CoV-2 B.1.620 lineage

In a recently published Nature Communications study, the authors describe the B.1.620 lineage discovered in Lithuania.

27 Oct 2021

Study uncovers how novel coronavirus disrupts normal cell defenses to hijack human host cells

A UBC-led research team has uncovered how the virus responsible for causing COVID-19 escapes destruction in infected cells, allowing SARS-CoV-2 to persist and continue spreading in the human body.

27 Oct 2021

Study of SARS-CoV-2 antibody seroprevalence among domestic cats

Researchers from the University of Veterinary Medicine Hannover have been investigating the spread of the disease in domestic cats in Europe.

27 Oct 2021

Model for the simulation of SARS-CoV-2 community transmission in congregate facilities

Researchers have examined the factors that caused the most significant outbreaks in congregate settings such as care homes and prisons.

27 Oct 2021

New study explains why Delta is so easily transmitted and infects people quickly

The Delta variant of SARS-CoV-2 has swept the globe, becoming the dominant variant within just a few months. A new study from Boston Children's Hospital, published today in Science, explains why Delta is so easily spread and infects people so quickly, and suggests a more targeted strategy for developing future COVID-19 vaccines and treatments.

27 Oct 2021

Spike Protein News and Research

Study reassures the safety, immunogenicity of COVID-19 vaccines for patients with rheumatic diseases

Evidence antibodies targeting HCoV-OC43 are robustly boosted in response to SARS-CoV-2 but not vaccination

SARS-CoV-2 antibodies persisting for nearly a year, including to delta: NZ study

COVID-19 antibody levels stay more durable in vaccinated people with prior SARS-CoV-2 infection

Curcumin, a bioactive component of turmeric, effectively neutralizes SARS-CoV-2 in vitro

Identification of novel nanobodies to specifically target SARS-CoV-2 replication protein

Emerging SARS-CoV-2 variant A.30 efficiently evades vaccine-induced immunity

The impact of SARS-CoV-2 variants on the COVID-19 epidemic in South Africa

Study uncovers unknown effects of COVID-19 virus on the immune system

How long does natural or vaccine-induced immunity to COVID last?

Structure of human-infecting canine coronavirus HuPn-2018 spike glycoprotein

Study finds one mRNA vaccine dose after SARS-CoV-2 infection produces highest neutralizing antibody titers

Panel of broadly neutralizing SARS-CoV-2 nanobodies for immune assay application

Japanese study on SARS-CoV-2 breakthrough infections

The difference in the dynamics of SARS-COV-2 variants

A study on the SARS-CoV-2 B.1.620 lineage

Study uncovers how novel coronavirus disrupts normal cell defenses to hijack human host cells

Study of SARS-CoV-2 antibody seroprevalence among domestic cats

Model for the simulation of SARS-CoV-2 community transmission in congregate facilities

New study explains why Delta is so easily transmitted and infects people quickly

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News